Jantoven and Ibrance drug interactions - a phase IV clinical study of FDA data
Summary:
Drug interactions are reported among people who take Jantoven (warfarin sodium) and Ibrance (palbociclib). Common drug interactions include fatigue among females.
The phase IV clinical study analyzes what interactions people have when they take Jantoven and Ibrance. It is created by eHealthMe based on reports of 17 people who take the same drugs from the FDA, and is updated regularly.
What is Jantoven?
Jantoven has active ingredients of warfarin sodium. It is often used in atrial fibrillation/flutter. eHealthMe is studying from 1,608 Jantoven users. Check the latest studies of Jantoven.
What is Ibrance?
Ibrance has active ingredients of palbociclib. eHealthMe is studying from 104,434 Ibrance users. Check the latest studies of Ibrance.
17 people who take Jantoven and Ibrance together, and have interactions are studied.
What are the common drug interactions of Jantoven and Ibrance, by gender? *:
female:
- Fatigue (feeling of tiredness)
- Anxiety
- Lung disorder (lung disease)
- White blood cell count decreased
- Herpes zoster
- Neoplasm progression (growth of tumour)
- Arthritis (form of joint disorder that involves inflammation of one or more joints)
- Arthropathy
- Death
- Alopecia (absence of hair from areas of the body)
male:
n/a
What are the common drug interactions of Jantoven and Ibrance, by age (0-1 to 60+)? *:
0-1:
n/a
2-9:
n/a
10-19:
n/a
20-29:
n/a
30-39:
n/a
40-49:
n/a
50-59:
- Decreased appetite
- Dysgeusia (disorder of the sense of taste)
- Nausea (feeling of having an urge to vomit)
60+:
- Fatigue (feeling of tiredness)
- Anxiety
- Neoplasm progression (growth of tumour)
- Pain in extremity
- Arthritis (form of joint disorder that involves inflammation of one or more joints)
- Arthropathy
- Dyspnoea (difficult or laboured respiration)
- Lung disorder (lung disease)
- Death
- Alopecia (absence of hair from areas of the body)
What are the existing conditions these people have? *
- Breast Cancer Female: 5 people, 29.41%
- Lymphoma (cancer that begins in immune system cells): 4 people, 23.53%
- Breast Cancer: 4 people, 23.53%
- High Blood Pressure: 4 people, 23.53%
- Vitamin C Decreased: 3 people, 17.65%
- Breast Cancer Metastatic: 3 people, 17.65%
- Cardiac Disorder: 3 people, 17.65%
- Immune System Disorder: 3 people, 17.65%
- Arthropathy: 3 people, 17.65%
- Type 2 Diabetes: 3 people, 17.65%
* Approximation only. Some reports may have incomplete information.
Do you take Jantoven and Ibrance?
- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously
Related studies:
Effectiveness of, side effects of, and alternative drugs to the 2 drugs:
Browse all drug interactions of Jantoven and Ibrance:
a b c d e f g h i j k l m n o p q r s t u v w x y zSub-studies by gender and age:
Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+
Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+
Browse all side effects of Jantoven:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all side effects of Ibrance:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all interactions between Jantoven and drugs from A to Z:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all interactions between Ibrance and drugs from A to Z:
a b c d e f g h i j k l m n o p q r s t u v w x y zHow the study uses the data?
The study uses data from the FDA. It is based on warfarin sodium and palbociclib (the active ingredients of Jantoven and Ibrance, respectively), and Jantoven and Ibrance (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Drug interactions of Nasacort and Miacalcin - 19 seconds ago
- Drug interactions of Methylphenidate Hydrochloride and Nexium - 20 seconds ago
- Drug interactions of Omeprazole and Ritalin La - 23 seconds ago
- Drug interactions of Amoxicillin and Hawthorn - 27 seconds ago
- Drug interactions of Cardura and Indocin - 33 seconds ago
- Drug interactions of Spiriva and Flavin - 37 seconds ago
- Could Gilotrif cause Rash Pustular? - 43 seconds ago
- Could Amlodipine Besylate cause Flatulence? - 44 seconds ago
- Drug interactions of Omega 6 and Vitamin C - 44 seconds ago
- Could Sildenafil Citrate cause Coronary Heart Disease? - 44 seconds ago